High Point Pharmaceuticals, LLC

Leo-pharma A/s

Novo Nordisk A/s

Japan Tobacco Inc.

Novozymes A/s

Novo Nordisk Pharmaceuticals, Inc.

Enkam Pharmaceuticals A/s

Nero Nordisk A/s

Soren Ebdrup

Henrik Sune Andersen

Poul Jacobsen

Per Vedso

Takashi Inaba

Holger C Hansen

Heinz-Josef Deussen

Takashi Watanabe

Magali Zundel

Johannes Cornelis De Jong

Tsubasa Takeichi

Akinobu Higashi

Hiromu Takiguchi

Kim Lebek Jensen

Per Vedsoe

Jan Bornholdt

Per Sauerberg

Dharma Rao Polisetti

Shamkant Anant Patkar

Ingrid Pettersson

John Paul Kilburn

Vladimir Berezin

Elisabeth Bock

Suparna Gupta

Peter Rahbek Ostergaard

Anders Klarskov Petersen

Carsten Mailand Hjort

Miroslav Havranek

Pavel Pihera

Gita Camilla Tejlgaard Kampen

Soren Christensen

Tanja Maria Greve

Kim Troensegaard Nielsen

Boris Klementiev

The present invention provides processes for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives, which are useful as a Janus kinase (JAK) inhibitor, intermediates thereof, and processes for preparing the intermediates. The present invention provides processes for preparing 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile using salts of (3S,4R)-1-benzyl-3-methyl-1,6-diazaspiro[3.4]octane with organic acids.

Process for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives and synthetic intermediates thereof

The present invention relates to the crystalline, polymorphic Form C of the calcimimetic compound {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid, to methods of preparation thereof, to methods of characterization thereof by single crystal X-Ray crystallography (XRC), X-Ray Powder diffractometry, attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy, Solid State NMR spectroscopy and Differential Scanning Calorimetry (DSC), and to its use. The invention also relates to the preparation of Form C by crystallization from a saturated solution of {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid in the presence of crystallization seeds of Form C, or alternatively by conversion of an amorphous starting material into the different crystalline polymorphic Form X by crystallization of {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid, followed by a solid solution transformation thereof into the desired polymorphic Form C.

Polymorphic form of a calcimimetic compound

Embodiments of the present invention provide adamantyl benzamide derivatives and pharmaceutical compositions comprising adamantyl benzamide derivatives. Methods of use of such compounds and compositions to modulate the activity of 11&#x3b2;-hydroxysteroid dehydrogenase type 1 (11&#x3b2;HSD1) in a subject are also provided.

Adamantyl benzamide derivatives

Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11&#x3b2;-hydroxysteroid dehydrogenase type 1 (11&#x3b2;HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.

N-adamantyl benzamides as inhibitors of 11-&#x3b2;-hydroxysteroid dehydrogenase

N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase

The present invention relates to novel compounds comprising at most 13 contiguous amino acid residues derived from the fibronectin type 3,11 module of neural cell adhesion molecule (NCAM), or a variant or fragment thereof, capable of interacting with an FGFR and thereby the compounds are capable of inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity or survival of cells. Further, the present invention relates to the use of the compounds for production of a medicament for treatment of conditions and diseases, in which NCAM or FGFR play a prominent role.

Peptides derived from NCAM (FGLs)

The present invention describes phenoxy-acetic acids and pharmaceutical compositions containing the same and methods of using the same. The phenoxy-acetic acids are activators of PPAR-&#x3b4; and should be useful for treating conditions mediated by the same.

Phenoxy acetic acids as PPAR delta activators

The use of substituted amides for modulating the activity of 11&#x3b2;-hydroxysteroid dehydrogenase type 1 (11&#x3b2;HSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, of the general formula I. Their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11&#x3b2;HSDI and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable. 

11-beta-hydroxysteroid dehydrogenase type 1 active compounds

The use of substituted amides for modulating the activity of 11&#x3b2;-hydroxysteroid dehydro-genase type 1 (11&#x3b2;HSD1) and the use of these compounds as pharmaceutical composi-tions, are described. Also a novel class of substituted amides, their use in therapy, phar-maceutical compositions comprising the compounds, as well as their use in the manufac-ture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11&#x3b2;HSD1 and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active gluco-corticoid is desirable.

Pharmaceutical use of substituted amides

Novel substituted amide inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11&#x3b2;-hydroxysteroid dehydrogenase type 1 (11&#x3b2;HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.

A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11&#x3b2;-hydroxy-steroid dehydrogenase type 1 (11&#x3b2;HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome. 

11&#x3b2;-hydroxysteroid dehydrogenase type 1 active compounds

The use of substituted amides for modulating the activity of 11-hydroxysteroid dehydrogenase type 1 (11HSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11HSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

Growing community of inventors

Roskilde, Denmark

Soren Ebdrup